Abbott Laboratories $ABT Shares Acquired by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 398.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,186 shares of the healthcare product maker’s stock after purchasing an additional 12,140 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Abbott Laboratories were worth $1,378,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ABT. Lipe & Dalton raised its position in shares of Abbott Laboratories by 11.3% in the 2nd quarter. Lipe & Dalton now owns 1,580 shares of the healthcare product maker’s stock worth $143,000 after buying an additional 160 shares during the period. Empirical Finance LLC lifted its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Empirical Finance LLC now owns 60,640 shares of the healthcare product maker’s stock valued at $5,502,000 after purchasing an additional 2,029 shares in the last quarter. Nykredit A S purchased a new position in shares of Abbott Laboratories in the second quarter valued at $49,778,000. Range Advisory LLC grew its holdings in Abbott Laboratories by 21.3% during the 2nd quarter. Range Advisory LLC now owns 3,176 shares of the healthcare product maker’s stock valued at $288,000 after purchasing an additional 557 shares in the last quarter. Finally, Brown Lisle Cummings Inc. increased its stake in Abbott Laboratories by 8.4% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 5,100 shares of the healthcare product maker’s stock worth $463,000 after buying an additional 394 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. BTIG Research lifted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. TD Cowen restated a “buy” rating and set a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Citigroup lifted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Price Performance

NYSE:ABT traded down $2.67 during mid-day trading on Tuesday, reaching $105.66. 11,397,135 shares of the stock were exchanged, compared to its average volume of 11,627,073. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The business has a fifty day moving average price of $105.04 and a 200 day moving average price of $99.95. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a market capitalization of $182.82 billion, a PE ratio of 34.19, a PEG ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.